Liposomal amikacin for inhalation (LAI) + placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Infections, Nontuberculous

Conditions

Mycobacterium Infections, Nontuberculous

Trial Timeline

Apr 19, 2012 → Jun 18, 2015

NCT ID

NCT01315236

About Liposomal amikacin for inhalation (LAI) + placebo

Liposomal amikacin for inhalation (LAI) + placebo is a phase 2 stage product being developed by Insmed for Mycobacterium Infections, Nontuberculous. The current trial status is completed. This product is registered under clinical trial identifier NCT01315236. Target conditions include Mycobacterium Infections, Nontuberculous.

What happened to similar drugs?

3 of 8 similar drugs in Mycobacterium Infections, Nontuberculous were approved

Approved (3) Terminated (1) Active (4)

✅clarithromycin, rifabutinPfizerApproved

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

🔄Ethambutol hydrochloride + Clarithromycin + AzithromycinPfizerPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)InsmedPhase 3

🔄LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01315236	Phase 2	Completed	Apr 19, 2012	Jun 18, 2015	Mycobacterium Infections, Nontuberculous

Competing Products

20 competing products in Mycobacterium Infections, Nontuberculous

See all competitors

Product	Company	Stage	Hype Score
Trifluridine	Amgen	Pre-clinical	26
clarithromycin, rifabutin	Pfizer	Approved	43
Azithromycin	Pfizer	Pre-clinical	26
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	40
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Approved	43
Tigecycline	Pfizer	Phase 2	35
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	37
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	37
LAI plus multi-drug regimen	Insmed	Phase 2	32
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	37
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin	Innoviva	Phase 2	36
Molgramostim nebulizer solution	Savara	Phase 2	21
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	29
Epetraborole + Epetraborole + Placebo + Placebo	AN2 Therapeutics	Phase 2	32
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	17
RHB-204 + Placebo	RedHill Biopharma	Phase 3	22